Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma

Journal of Medical Virology

Volumn 85, Issue 11, 2013, Pages 1900-1906

  Matsui, Takeshi ^a,b   Kang, Jong Hon ^b   Nojima, Masanori ^c   Tomonari, Akiko ^b   Aoki, Hironori ^b   Yamazaki, Hajime ^b   Yane, Kei ^b   Tsuji, Kunihiko ^b   Andoh, Seisho ^b   Andoh, Sachiko ^b   Sakai, Hajime ^b   Maemori, Masayo ^b   Maguchi, Hiroyuki ^b   Tanaka, Yasuhito ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Hepatitis B virus; Lymphocyte; Reactivation

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; METHOTREXATE; PIRARUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; EARLY DIAGNOSIS; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PERIPHERAL T CELL LYMPHOMA; SEROLOGY; T CELL LYMPHOMA; VIRUS REACTIVATION;

HEPATITIS B VIRUS;

CHEMOTHERAPY; HEPATITIS B VIRUS; LYMPHOCYTE; REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; VIRAL LOAD; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84883051828     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23694     Document Type: Article

References (20)

1. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. 1995. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290.
2. Cheung WI, Chan HL, Leung VK, Tse CH, Fung K, Lin SY, Wong A, Wong VW, Chau TN. 2010. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol 47:193-195.
3. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, Baldelli F. 2010. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 38:58-61.
4. Gu XB, Yang XJ, Wang D, Hua Z, Xu YQ, Lu ZH. 2009. Relationship between serum HBV DNA level and HBV-specific, nonspecific cytotoxic T lymphocytes and natural killer cells in patients with chronic hepatitis B. Chin Med J 122:2129-2132.
5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M. 2005. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732.
6. Hirohito Tsubouchi HK, Kendo K, Satoshi M, Isao S, Eiji T, Takafumi I, Masashi M, Kazuyuki S, Shinsyo Y, Hisataka M, Toshifumi H, Norio H, Norihiro K, Tomoo F, Hiromi I, Yasuhiko S, Hiroshi Y, Akio I, Yasuhiro T, Kazuaki I, Makoto O, Hirofumi U, Nobuaki N, Takafumi N, Shinichiro T, Shinichi K, Koji Y, Ryujin E, Yasuhito T, Takeji U, Kotaro K. 2009. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection-Joint report of the intractable liver diseases study group of Japan and the Japanese study group of the standard antiviral therapy for viral hepatitis. Kanzo 50:38-42.
7. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. 2006. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68.
8. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. 2011. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46:9-16.
9. Li J, Han Y, Jin K, Wan Y, Wang S, Liu B, Liu Y, Lu S, Huang Z. 2011. Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection. Virol J 8:199.
10. Matsubara N, Kusano O, Sugamata Y, Itoh T, Mizuii M, Tanaka J, Yoshizawa H. 2009. A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection. Transfusion 49:585-595.
11. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. 2010. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116:4769-4776.
12. Shinkai N, Tanaka Y, Matsuura K, Kani S, Naganuma H, Mizokami M. 2010. Evaluation and application of a newly developed highly sensitive HBsAg chemiluminescent enzyme immunoassay for chronic hepatitis B patients. Rinsho Byori 58:1078-1084.
13. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M. 2011. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 83:412-418.
14. Tur-Kaspa R, Laub O. 1990. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J Hepatol 11:34-36.
15. Wu JM, Huang YH, Lee PC, Lin HC, Lee SD. 2009. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43:496-498.
16. Wursthorn K, Wedemeyer H, Manns MP. 2010. Managing HBV in patients with impaired immunity. Gut 59:1430-1445.
17. Yagci M, Ozkurt ZN, Yegin ZA, Aki Z, Sucak GT, Haznedar R. 2010. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 15:240-244.
18. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611.
19. Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Iida S, Sugauchi F, Tanaka Y, Mizokami M, Ueda R. 2010. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. Int J Hematol 91:844-849.
20. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Kimura S, Koike K. 1998. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27:1377-1382.